EUVIMEDEUVIMED entdecken
Crossref

An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen

Sanaz Majidi, Khosrow Aghaiypour Kolyani, Meisam Akrami, Maryam Dadar

Molecular Biotechnology · 2026

DOI: 10.1007/s12033-025-01409-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biotechnology, 2026. Verfasst von Sanaz Majidi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology & Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Behesht Aein Laboratory Complex (MABA), Razi Vaccine and Serum Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since December 2019, the SARS-CoV-2 virus has caused the global COVID-19 pandemic. Antiviral and anti-inflammatory treatments have had limited success, positioning vaccine development as a key strategy for public health. This study constructed a chimeric S1 protein fused to a human Fc domain using the Pichia pastoris expression system. Yeast expression system was selected for its low-cost and relatively easier process comparing mammalian and insect. In addition, two human commercial vaccines including human Hepatitis B virus and human papilloma virus are produced currently in yeast system. The chimeric protein named S1Fc was codon-optimized and expressed via the pPICZaA vector as pPICZaA-S1Fc construct. This construct consists of 918 amino acids: 673 amino acids of the S1 protein (N-terminal) linked to 227 amino acids from the human IgG1 Fc region (C-terminal) via 18 amino acids linker. Two yeast strains, a standard glycosylating strain and a mammalian-like GlycoSwitch strain, were selected for expression. SDS-PAGE and western blot analyses indicated successful S1Fc expression in both strains, with a molecular weight of approximately 130 kDa. The GlycoSwitch strain demonstrated enhanced antigenicity in ELISA, indicating a glycosylation pattern more similar to the native viral S1 protein. Purification was achieved using a protein G chromatography column, yielding 14.6 µg/ml in the GlycoSwitch strain and 18.9 µg/ml in the standard strain. These findings highlight the Pichia pastoris expression system as a cost-effective platform for S1Fc protein production, meriting further study as a potential vaccine antigen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2COVID-19 VaccinesCOVID-19Antigens, ViralHumansSaccharomycetalesRecombinant Fusion ProteinsAntibodies, ViralPichiaProtein Engineering

Stichwörter der Autor:innen

Pichia pastorisAnti-covidELISAExpression systemSARS-CoV-2

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 VaccinesRecombinant Fusion ProteinsAntibodies, ViralAntigens, Viral

Autor:innen und Institutionen

  • Department of Microbiology & Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
  • Biotechnology Department, Behesht Aein Laboratory Complex (MABA), No 193 Jala Al Ahmad Avenue, Tehran, Iran. khosrow_ak@yahoo.com.
  • Department of Genomics and Genetic Engineering, Razi Vaccine and Serum Research Institute (RVSRI), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. khosrow_ak@yahoo.com.
  • Science Department, Science Faculty, Tehran Central Branch, Islamic Azad University, Tehran, Iran.
  • Biotechnology Department, Behesht Aein Laboratory Complex (MABA), No 193 Jala Al Ahmad Avenue, Tehran, Iran.
  • Department of Genomics and Genetic Engineering, Razi Vaccine and Serum Research Institute (RVSRI), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

Förderung

  • Behesht Aein Laboratory Complex (MABA)
  • Razi Vaccine and Serum Research Institute

Zitieren

APA

Majidi, S., Aghaiypour Kolyani, K., Akrami, M., & Dadar, M. (2026). An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen. Molecular Biotechnology. https://doi.org/10.1007/s12033-025-01409-5

Vancouver

Majidi S, Aghaiypour Kolyani K, Akrami M, Dadar M. An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen. Molecular Biotechnology. 2026. doi:10.1007/s12033-025-01409-5

BibTeX
@article{Majidi2026,
  author = {Majidi, Sanaz and Aghaiypour Kolyani, Khosrow and Akrami, Meisam and Dadar, Maryam},
  title = {An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen},
  journal = {Molecular Biotechnology},
  year = {2026},
  doi = {10.1007/s12033-025-01409-5}
}
Kostenlos starten →